Effects of clarithromycin on NK and NK T-cell expression patterns in patients treated with pomalidomide, ixazomib, dexamethasone. Peripheral blood samples taken on day 15 (after 2 weeks of pomalidomide, ixazomib, dexamethasone) and on cycle 2 day 1 (after the final week of pomalidomide, ixazomib, dexamethasone in combination with 2 weeks of clarithromycin) were analyzed by flow cytometry and compared to identify potential immunomodulatory effects of clarithromycin. Postclarithromycin samples showed increased percentages of NKG2A+, CD56 Bright, CD16 negative NK cells (left) and a decrease in the percentage of CD56 Bright, CD16 Dim NK T cells (right).